Table 3:

Risk for outcome development. In all analyses, prescription of potentially nephrotoxic medications was associated with an increased incidence of new or worsening kidney dysfunction.

Analysis Group	Sample	CKDa	Composite of CKD, Readmit with AKI or Death
All patients 3 year follow up (n=2461)	Hazard Ratiob	1.38 (1.24–1.54)	1.41 (1.28–1.56)
	P Value	<0.001	<0.001
	Adjusted Hazard Ratioc	1.39 (1.24–1.56)	1.44 (1.30–1.59)
	P Value	<0.001	<0.001
All patients 1 year follow up (n=2461)	Hazard Ratioc	1.36 (1.17–1.58)	1.44 (1.26–1.63)
	P Value	<0.001	<0.001
Analysis of only patients with measured baseline eGFR (n=1599)	Hazard Ratioc	1.35 (1.17–1.55)	1.40 (1.23–1.58)
	P Value	<0.001	<0.001
Analysis of only patients with heart failure (n=1153)	Hazard Ratioc	1.32 (1.14–1.54)	1.37 (1.19–1.57)
	P Value	<0.001	<0.001
Analysis of only patients without heart failure (n=1308)	Hazard Ratioc	1.48 (1.25–1.76)	1.53 (1.31–1.78)
	P Value	<0.001	<0.001
Analysis of only patients with AKI recovery by discharged (n=1736)	Hazard Ratioc	1.24 (1.08–1.43)	1.32 (1.17–1.49)
	P Value	<0.001	<0.001
Analysis of only patients with baseline eGFR < 60 (n=1341)	Hazard Ratioc	1.41 (1.21–1.65)	1.47 (1.29–1.68)
	P Value	<0.001	<0.001

CKD: chronic kidney disease; Dx: diagnosis; eGFR: estimated glomerular filtration rate; AKI: acute kidney injury; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; NTXN: potentially nephrotoxic medication

^a:Outcome defined as de novo or progressive CKD.

^b:Reported as hazard ratio (95% confidence interval)

^c:Adjusted for gender, age, hospital length of stay. ICU during hospitalization, BMI, baseline eGFR, cardiovascular disease, CHF (in models not separating heart failure patients), PVD, maximum AKI severity, persistent AKI, and change in eGFR during hospitalization.

^d:Recovery from AKI was defined as serum creatinine < 1.5 times baseline[10]